These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16958594)

  • 21. Variation in paraoxonase-1 activity and atherosclerosis.
    Soran H; Younis NN; Charlton-Menys V; Durrington P
    Curr Opin Lipidol; 2009 Aug; 20(4):265-74. PubMed ID: 19550323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The paraoxonases: role in human diseases and methodological difficulties in measurement.
    Camps J; Marsillach J; Joven J
    Crit Rev Clin Lab Sci; 2009; 46(2):83-106. PubMed ID: 19255916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of biologically active δ-lactone eicosanoids as paraoxonase substrates.
    Teiber JF; Xiao J; Kramer GL; Ogawa S; Ebner C; Wolleb H; Carreira EM; Shih DM; Haley RW
    Biochem Biophys Res Commun; 2018 Oct; 505(1):87-92. PubMed ID: 30241945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae.
    Soran H; Schofield JD; Liu Y; Durrington PN
    Curr Opin Lipidol; 2015 Aug; 26(4):247-56. PubMed ID: 26103614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Paraoxonase: its multiple functions and pharmacological regulation].
    Fridman O; Fuchs AG; Porcile R; Morales AV; Gariglio LO
    Arch Cardiol Mex; 2011; 81(3):251-60. PubMed ID: 21975240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Human plasma paraoxonase (HuPON1): an anti-atherogenic enzyme with organophosphate hydrolase activity].
    Josse D; Masson P
    Ann Pharm Fr; 2001 Apr; 59(2):108-18. PubMed ID: 11320335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paraoxonases and infectious diseases.
    Camps J; Iftimie S; García-Heredia A; Castro A; Joven J
    Clin Biochem; 2017 Sep; 50(13-14):804-811. PubMed ID: 28433610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Directed evolution of serum paraoxonase PON3 by family shuffling and ancestor/consensus mutagenesis, and its biochemical characterization.
    Khersonsky O; Rosenblat M; Toker L; Yacobson S; Hugenmatter A; Silman I; Sussman JL; Aviram M; Tawfik DS
    Biochemistry; 2009 Jul; 48(28):6644-54. PubMed ID: 19492856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy.
    Li C; Gu Q
    Nephrology (Carlton); 2009 Aug; 14(5):514-20. PubMed ID: 19207863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity.
    Tavori H; Khatib S; Aviram M; Vaya J
    Bioorg Med Chem; 2008 Aug; 16(15):7504-9. PubMed ID: 18572410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses.
    Laplaud PM; Dantoine T; Chapman MJ
    Clin Chem Lab Med; 1998 Jun; 36(7):431-41. PubMed ID: 9746266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the Role of Paraoxonase-1 and Chemokine Ligand 2 (C-C motif) in Metabolic Alterations Linked to Inflammation and Disease. A 2021 Update.
    Camps J; Castañé H; Rodríguez-Tomàs E; Baiges-Gaya G; Hernández-Aguilera A; Arenas M; Iftimie S; Joven J
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease.
    Sztanek F; Seres I; Harangi M; Lőcsey L; Padra J; Paragh GJ; Asztalos L; Paragh G
    Nephrol Dial Transplant; 2012 Jul; 27(7):2866-72. PubMed ID: 22247228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lactonases with organophosphatase activity: structural and evolutionary perspectives.
    Draganov DI
    Chem Biol Interact; 2010 Sep; 187(1-3):370-2. PubMed ID: 20122908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The three-gene paraoxonase family: physiologic roles, actions and regulation.
    Précourt LP; Amre D; Denis MC; Lavoie JC; Delvin E; Seidman E; Levy E
    Atherosclerosis; 2011 Jan; 214(1):20-36. PubMed ID: 20934178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I.
    Gaidukov L; Viji RI; Yacobson S; Rosenblat M; Aviram M; Tawfik DS
    Biochemistry; 2010 Jan; 49(3):532-8. PubMed ID: 20025294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo.
    Gugliucci A
    Clin Chim Acta; 2014 Feb; 429():38-45. PubMed ID: 24280342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of highly purified human paraoxonase (PON1): association with human phosphate binding protein (HPBP) is essential for preserving its active conformation(s).
    Rochu D; Renault F; Cléry-Barraud C; Chabrière E; Masson P
    Biochim Biophys Acta; 2007 Jul; 1774(7):874-83. PubMed ID: 17556053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease.
    Mackness M; Durrington P; Mackness B
    Curr Opin Lipidol; 2004 Aug; 15(4):399-404. PubMed ID: 15243212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Directed evolution of recombinant serum paraoxonase (PON) variants.
    Aharoni A; Tawfik DS
    Discov Med; 2004 Apr; 4(21):120-4. PubMed ID: 20705007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.